The combination of U.S. tariff policies, the implementation of regenerative medicine regulations, and the peak season of the medical aesthetics market has created a strong tailwind for Taiwanese biotech companies such as Bora Pharmaceuticals, Lotus Pharmaceutical, Tanvex BioPharma, EVER SUPREME BIO TECHNOLOGY, UnicoCell Biomed, CHLITINA HOLDING, Luo Lih-Fen Holding, STEMINENT BIOTHERAPEUTICS, BIONET, Taiwan Bio Therapeutics, YungShin Pharm, EASYWELL BIOMEDICALS, Polaris Group, and StemCyte, positioning them as key growth leaders in their sector.
The Trump administration’s decision to impose a 100% tariff on all imported branded and patented drugs starting October—exempting only U.S.-made products—has triggered a global reshaping of pharmaceutical manufacturing. Taiwanese biotech companies with U.S. production facilities, including Bora, Lotus, YungShin, EASYWELL, Tanvex BioPharma, Polaris, and StemCyte, are among the primary beneficiaries, emerging as major winners.
Bora Pharmaceuticals, which strategically invested in the U.S. early on, has built a comprehensive production chain spanning oral drugs, injectables, and biologics. This was achieved through acquisitions of USL and Emergent BioSolutions’ sterile injectable facilities, the rare disease company Pyros, and by becoming the largest shareholder of Tanvex, turning its U.S. presence into a tangible competitive advantage under the new tariff regime.
Lotus Pharmaceutical spent $658 million to acquire Alvogen US, gaining a large-scale production facility in New York State with integrated R&D, manufacturing, and sales capabilities. This enabled the company to bypass the tariff impact and enter the ranks of the world’s top 20 specialty pharmaceutical companies. Meanwhile, YungShin Pharm built its own U.S. facility with 12 approved products, StemCyte’s cell therapy products have obtained FDA approval, and Taiwan Bio Therapeutics plans to establish a production facility in collaboration with the Mayo Clinic in Q4—each creating new operational advantages.
The second driving factor is favorable regulatory developments. Taiwan’s Legislative Yuan passed the Regenerative Medicine Act and the Regenerative Medical Products Regulation, which will take effect January 1. Under the new law, products that have completed Phase 2 clinical trials demonstrating safety and preliminary efficacy can apply for a five-year conditional approval, opening new pathways for the domestic cell therapy industry.
In this context, UnicoCell Biomed has met endpoints for Phase 2 trials in degenerative arthritis and chronic kidney disease, with enrollment expected to complete this year. EVER SUPREME BIO TECHNOLOGY’s CAR-T clinical results are positive, with Phase 2 planned for next year. STEMINENT Biotherapeutics has submitted a conditional approval application in Japan for spinocerebellar atrophy. BIONET is advancing autologous adipose-derived stem cell therapies for arthritis and soft tissue repair, while Locus Cell is expanding overseas orders. Its GMP facility in Zhubei will begin operations in 2026 and has already secured production for an Australian dry eye therapy, demonstrating international CDMO competitiveness. These developments are drawing significant market attention.
Resource: 美國製造、再生醫療、醫美三利多加持 保瑞、美時等受惠公司一次看
